Therapeutic Targeting of Inflammation and Virus Simultaneously Ameliorates Influenza Pneumonia and Protects from Morbidity and Mortality
Viruses · 2023
DOI: 10.3390/v15020318 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Pratikshya Pandey und 7 weiteren Autor:innen. Beteiligte Einrichtung: Viral Immunology and Immunopathology Group, Tasmanian School of Medicine, University of Tasmania, Hobart, TAS 7000, Australia. Hauptthemen laut MEDLINE: Influenza, Human, COVID-19, Pneumonia, Influenza A virus. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council of Australia, Medical Protection Society of Tasmania Inc..
Abstract (Originalsprache)
Influenza pneumonia is a severe complication caused by inflammation of the lungs following infection with seasonal and pandemic strains of influenza A virus (IAV), that can result in lung pathology, respiratory failure, and death. There is currently no treatment for severe disease and pneumonia caused by IAV. Antivirals are available but are only effective if treatment is initiated within 48 h of onset of symptoms. Influenza complications and mortality are often associated with high viral load and an excessive lung inflammatory cytokine response. Therefore, we simultaneously targeted the virus and inflammation. We used the antiviral oseltamivir and the anti-inflammatory drug etanercept to dampen TNF signaling after the onset of clinical signs to treat pneumonia in a mouse model of respiratory IAV infection. The combined treatment down-regulated the inflammatory cytokines TNF, IL-1β, IL-6, and IL-12p40, and the chemokines CCL2, CCL5, and CXCL10. Consequently, combined treatment with oseltamivir and a signal transducer and activator of transcription 3 (STAT3) inhibitor effectively reduced clinical disease and lung pathology. Combined treatment using etanercept or STAT3 inhibitor and oseltamivir dampened an overlapping set of cytokines. Thus, combined therapy targeting a specific cytokine or cytokine signaling pathway and an antiviral drug provide an effective treatment strategy for ameliorating IAV pneumonia. This approach might apply to treating pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Viral Immunology and Immunopathology Group, Tasmanian School of Medicine, University of Tasmania, Hobart, TAS 7000, Australia.
- Infection and Immunity Group, Department of Immunology, The John Curtin School of Medical Research, Australian National University, Canberra, ACT 2601, Australia.
- Tasmanian School of Medicine, University of Tasmania, Hobart, TAS 7000, Australia.
ORCID-Profile: Zahrah Al Rumaih, Ma Junaliah Tuazon Kels, Esther Ng, Gunasegaran Karupiah
Förderung
- National Health and Medical Research Council of Australia
- Medical Protection Society of Tasmania Inc.
Zitieren
APA
Pandey, P., Al Rumaih, Z., Kels, M. J. T., Ng, E., Kc, R., Malley, R., Chaudhri, G., & Karupiah, G. (2023). Therapeutic Targeting of Inflammation and Virus Simultaneously Ameliorates Influenza Pneumonia and Protects from Morbidity and Mortality. Viruses. https://doi.org/10.3390/v15020318
Vancouver
Pandey P, Al Rumaih Z, Kels MJT, Ng E, Kc R, Malley R, et al. Therapeutic Targeting of Inflammation and Virus Simultaneously Ameliorates Influenza Pneumonia and Protects from Morbidity and Mortality. Viruses. 2023. doi:10.3390/v15020318
BibTeX
@article{Pandey2023,
author = {Pandey, Pratikshya and Al Rumaih, Zahrah and Kels, Ma Junaliah Tuazon and Ng, Esther and Kc, Rajendra and Malley, Roslyn and Chaudhri, Geeta and Karupiah, Gunasegaran},
title = {Therapeutic Targeting of Inflammation and Virus Simultaneously Ameliorates Influenza Pneumonia and Protects from Morbidity and Mortality},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15020318}
}
EUVIMED